Slides
Page 1
Q3 2026 Earnings Presentation November 4, 2026 BRUKER CORPORATION (NASDAQ: BRKR) Frank H. Laukien, President & Chief Executive Officer Gerald Herman, Executive Vice President & Chief Financial Officer Joe Kostka, Director, Investor Relations
Page 2
| |© 2022 Bruker + -Bruker Confidential- © 2026 Bruker | | BRUKER CORPORATION Safe Harbor Statement November 4, 2026Q3 2026 Earnings Presentation 2 Any statements contained in this presentation which do not describe historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding our fiscal year 2026 and beyond financial outlook, our outlook for reported revenue growth, organic revenue growth, M&A revenue growth contributions, CER currency revenue growth, margin improvements, foreign currency translation revenue impact, EPS, non-GAAP EPS, and CER non-GAAP EPS growth; management’s expectations for the impact of foreign currency and acquisitions; the effects of our expanded cost savings initiatives; and for future financial and operational performance and business outlook; future economic conditions. Any forward-looking statements contained herein are based on current expectations, but are subject to risks and uncertainties that could cause actual results to differ materially from those indicated, including, but not limited to, (1) the length and severity of any disruption in US academic and government markets, a potential recession, and global economic conditions, (2) the impact of supply chain challenges, including inflationary pressures, or shortages or price spikes in high-performance memory chips or in liquid Helium, (3) the impact of wars, blockades, geopolitical instability and tensions and any sanctions, (4) the ongoing tensions between the United States and China, tariff increases or uncertainties and tariff and trade policy changes and restrictions, (5) continued volatility in the capital markets, (6) the impact of increased interest rates, (7) the integration and assumption of liabilities of businesses we have acquired or may acquire in the future, (8) our restructuring and cost-control initiatives, (9) changing technologies, product development and market acceptance of our products, (10) the cost and pricing of our products, manufacturing and outsourcing, competition, dependence on collaborative partners, key suppliers and third party distributors, capital spending and government funding policies, (11) changes in governmental regulations, intellectual property rights, and litigation, (12) the impact of foreign currency exchange rates, (13) our ability to service our debt obligations and fund our anticipated cash needs, (14) the effect of a concentrated ownership of our common stock, (15) the loss of key personnel, (16) payment of future dividends, (17) the impact (if any) of macroeconomic issues, including uncertainties related to trade policies or tariff regulations, and (18) other risk factors discussed from time to time in our filings with the Securities and Exchange Commission, or SEC. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2025, as may be updated by our quarterly reports on Form 10-Q. We expressly disclaim any intent or obligation to update these forward-looking statements other than as required by applicable law.
Page 3
Q3 2026 Business Update 3
Page 4
| |© 2022 Bruker + -Bruker Confidential- © 2026 Bruker | | Q3 2026: Significant Non-GAAP Operating Margin Expansion and Non-GAAP EPS Growth ❖ Revenue increase of $13.5M, or 1.6% ▪ Organic growth of +0.7%, with BSI down -0.4% and BEST up +11.8% ▪ M&A contribution of +1.7%, with CER growth of +2.4% ▪ FX headwind of -0.8% ❖ Non-GAAP gross margin 51.3%, up 120 bps ❖ Non-GAAP operating margin 16.3%, up 400 bps ❖ GAAP Loss per Share: -$0.81 ❖ Non-GAAP EPS: $0.56, up +24.4% ❖ BSI Book-to-Bill >1.0x Q3 2026 Performance; Year-over-Year Changes 860.5 874.0 Q3-25 Q3-26 $0.56 $0.45 Q3-26 Q3-25 +24.4% Revenues [$M] Non-GAAP EPS +1.6% Q3 Financials November 4, 2026Q3 2026 Earnings Presentation 4 Reconciliations of non-GAAP to GAAP financial measures are available in our earnings press release and at the end of this presentation.
Page 5
| |© 2022 Bruker + -Bruker Confidential- © 2026 Bruker | | $1.36 $1.23 YTD-26 YTD-25 Q3-26 YTD: Meaningful Non-GAAP Margin Expansion and Non-GAAP EPS Growth ❖ Revenue increase of $76.6M, or 3.1% ▪ Organic decline of -0.3%, with BSI down -1.0% and BEST up 8.3% ▪ M&A contribution of +1.9%, with CER growth of +1.6% ▪ FX tailwind of +1.5% ❖ Non-GAAP gross margin 51.1%, up 110 bps ❖ Non-GAAP operating margin 13.6%, up 220 bps ❖ GAAP Loss per Share: -$1.20 ❖ Non-GAAP EPS: $1.36, up +10.6% ❖ BSI organic bookings up mid single digits %; BSI Book-to-Bill >1.0x Q3 2026 YTD Performance; Year-over-Year Changes Revenues [$M] Non-GAAP EPS +3.1% Q3-YTD Financials Reconciliations of non-GAAP to GAAP financial measures are available in our earnings press release and at the end of this presentation. November 4, 2026Q3 2026 Earnings Presentation 5 +10.6% 2,459.3 2,535.9 YTD-25 YTD-26
Page 6
| |© 2022 Bruker + -Bruker Confidential- © 2026 Bruker | |November 4, 2026 6Q3 2026 Earnings Presentation GROUP OVERVIEW ▪ BioSystems revenue up low single digits % ▪ Strong Academic Medical and Biopharma revenue growth; softness in other aca/gov, and food testing ▪ Strong revenue growth in IR/Raman spectroscopy; softness in NMR ▪ Solid mass spectrometry order growth from acquisition of TOFWERK in Switzerland Bruker BioSystems Group ▪ BMID revenue up low single digits % ▪ Strength in Europe; softness in APAC and US ▪ Robust Molecular Dx revenue and order growth ▪ Modest growth in Microbiology Bruker Microbiology & Infection Diagnostics (BMID) Group Bruker Groups - YTD CER Performance YoY
Page 7
| |© 2022 Bruker + -Bruker Confidential- © 2026 Bruker | | 7 GROUP OVERVIEW Bruker Groups - YTD CER Performance YoY ▪ NANO CER revenue down low single digits % ▪ Strong Semi and biopharma revenues; weakness in aca/gov and industrial ▪ Revenue growth in US and Europe offset by softer APAC ▪ Strong AI-driven orders for memory and advanced packaging semi metrology tools Bruker NANO Group ▪ BEST CER revenue up 8%, net of intercompany eliminations ▪ Robust revenue growth at Research Instruments (RI), solid growth in superconductors ▪ Outstanding order growth from multi-year contracts for superconducting wire, fusion energy technologies, and high-energy physics tools Bruker Energy & Supercon Technologies (BEST) Segment November 4, 2026Q3 2026 Earnings Presentation
Page 8
| |© 2022 Bruker + -Bruker Confidential- © 2026 Bruker | |November 4, 2026 8Q3 2026 Earnings Presentation MIMETAS: A leading humanized Organ-on-a-Chip & NAM platform Acquisition expands preclinical solutions for drug discovery and disease biology research ➢ MIMETAS humanized microphysiological systems include organ-on-a-chip (OoC) models, also known as New Approach Methodologies (NAMs) ➢ MIMETAS combines physiological microfluidic 3D human cell organoids with membrane-less OoC interfaces ➢ NAMs complement preclinical animal testing ➢ MIMETAS synergies with Bruker multiomics, spatial biology and preclinical imaging tools for disease biology research, drug development and AI frontier models Annual revenues ~$10M, expected to grow in the double digits %, with accretive gross margins
Page 9
| |© 2022 Bruker + -Bruker Confidential- © 2026 Bruker | | November 4, 2026 9Q3 2026 Earnings Presentation iHUPO News: Advancing Functional Proteomics with Novel Workflows For Post-Genomic Drug Discovery and Disease Biology 2.0 Research Novel MultiDIA method on timsUltra • more peptides and protein groups • more isoforms, sequence variants, and protein regions missed by other MS-based or by affinity methods Advanced glycopeptide characterization on timsOmni • Fast, sensitive and selective trapped electron-based glycopeptide fragmentation Oligonucleotide and native RNA analysis on timsOmni • Native top-down analysis of folded RNA structures • Advanced oligonucleotide characterization for RNA drug targets or RNA drugs
Page 10
Q3 2026 Financial Update 10
Page 11
| |© 2022 Bruker + -Bruker Confidential- © 2026 Bruker | | Q3 2026 YEAR -OVER -YEAR COMPARISON Q3 2026 Selected Non-GAAP Financial Measures1 [$ m, except EPS] Q3 2026 Q3 2025 Δ Total Revenues 874.0 860.5 1.6% Gross Profit 448.3 430.9 4.0% Margin (% of revenues) 51.3% 50.1% 120 bps SG&A (213.8) (227.1) (5.9%) (% of revenues) 24.5% 26.4% R&D (92.0) (98.3) (6.4%) (% of revenues) 10.5% 11.4% Operating Income 142.6 105.9 34.7% Margin (% of revenues) 16.3% 12.3% 400 bps Tax Rate 28.4% 24.4% 400 bps Net Income2 86.3 67.9 27.1% EPS $0.56 $0.45 24.4% Shares Outstanding 153.2 152.0 0.8% ▪ Revenue increase of +1.6% ▪ Organic revenue growth +0.7% ▪ BSI organic decline of -0.4%; BEST organic growth of 11.8% ▪ Gross margin increase of 120 bps ▪ Operating margin increase of 400 bps: ▪ Driven by cost savings +300 bps and mix +90 bps ▪ Non-GAAP EPS of $0.56, up 24.4% Comments (year-over-year) 1Reconciliations of non-GAAP to GAAP financial measures are available in our earnings press release and at the end of this presentation. 2Attributable to Bruker common shareholders, Sum of items may not total due to rounding November 4, 2026Q3 2026 Earnings Presentation 11
Page 12
| |© 2022 Bruker + -Bruker Confidential- © 2026 Bruker | | YTD 2026 YEAR -OVER -YEAR COMPARISON Q3-26 YTD Selected Non-GAAP Financial Measures1 [$ m, except EPS] YTD 2026 YTD 2025 Δ Total Revenues 2,535.9 2,459.3 3.1% Gross Profit 1,296.7 1,229.0 5.5% Margin (% of revenues) 51.1% 50.0% 110 bps SG&A (664.1) (654.4) 1.5% (% of revenues) 26.2% 26.6% R&D (287.6) (295.6) (2.7%) (% of revenues) 11.3% 12.0% Operating Income 345.3 279.6 23.5% Margin (% of revenues) 13.6% 11.4% 220 bps Tax Rate 27.0% 25.5% 150 bps Net Income2 208.7 187.0 11.6% EPS $1.36 $1.23 10.6% Shares Outstanding 152.9 152.0 0.6% ▪ Revenue increase of 3.1% ▪ BSI organic decline of -1.0%; BEST organic growth of 8.3% ▪ Gross margin increase of 110 bps ▪ Operating margin increase of 220 bps: ▪ Driven by cost savings +280 bps, net US tariffs +60 bps, partially offset by volume/mix -50 bps and FX headwinds of -70 bps ▪ Non-GAAP EPS of $1.36, increase of 10.6%, including FX headwind of $0.05 Comments (year-over-year) 1Reconciliations of non-GAAP to GAAP financial measures are available in our earnings press release and at the end of this presentation. 2Attributable to Bruker common shareholders, Sum of items may not total due to rounding November 4, 2026Q3 2026 Earnings Presentation 12
Page 13
| |© 2022 Bruker + -Bruker Confidential- © 2026 Bruker | | Q3 YEAR -OVER -YEAR COMPARISON Q3 2026 Selected Cash Flow And Balance Sheet Measures [$M] Q3 2026 Q3 2025 Δ GAAP Net (Loss) Income (109.7) (58.5) (51.2) Depreciation & amortization 54.1 55.7 (1.6) Changes in working capital (18.0) (92.2) 74.2 Other items 191.8 61.8 130.0 Operating cash flow 118.2 (33.2) 151.4 Capital expenditures (21.5) (20.9) (0.6) Free cash flow (non-GAAP) 96.7 (54.1) 150.8 ▪ Free cash flow up +$151M yoy, driven by higher net income, excluding non-cash impairment of goodwill, and improved working capital ▪ Net leverage ratio of 2.4x as of September 30th ▪ Debt repayments of $58M in Q3-26 Comments (year-over-year) August 4, 2026Q2 2026 Earnings Presentation 13 [$M] Q3 2026 Q2 2026 Δ Cash, Equivalents & Short- term Investments $119.7 $184.9 (35.3%) Net (Debt)/ Cash $ (1,597.6) $ (1,641.8) (2.7%) WC-to-revenue ratio 0.42 0.42 ____
Page 14
FY 2026 Outlook 14
Page 15
| |© 2022 Bruker + -Bruker Confidential- © 2026 Bruker | | Updating FY 2026 Financial Outlook for Currency (as of November 4th, 2026) Non-GAAP Assumptions & YoY Estimates ▪ FY26 operating margin up 250-300 bps ▪ FX impact: ▪ Neutral to revenue ▪ Headwind to OPM ~50 bps ▪ Headwind to EPS of ~$0.05 ▪ Effective tax rate of 27.5% ▪ CAPEX: ~$110M ▪ FX assumptions (rates as of September 30, 2026): ➢ EUR = 1.13 USD; CHF = 1.20 USD; JPY = 0.0064 USD November 4, 2026Q3 2026 Earnings Presentation 15 FY 2026 Guidance (year-over-year %s) Revenue $3.52B to $3.56B Reported Revenue Growth +2.5% to +3.5% Organic revenue growth +1% to +2% M&A revenue contribution CER revenue growth approx. 1.5% +2.5% to +3.5% Non-GAAP EPS Reported EPS Growth $2.10 to $2.15 +15% to +17%
Page 16
Supplementary Financial Information* 16 * For preliminary financial statements, GAAP to Non-GAAP reconciliations, and other supplementary financial information, please refer to our Q3 2026 Earnings Press Release issued November 4th, 2026.